Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment ... MarketWatch (press release) Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, daclizumab, ocrelizumab) are also characterized. BioTrends Research Group, LLC provides syndicated and custom market research ... |
